Aster DM Healthcare Limited Share Price
Equities
ASTERDM
INE914M01019
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 555.25 INR | -3.65% |
|
-7.37% | -9.99% |
| 30/12 | Medcare Treats First International Sma Patient with Revolutionary Intrathecal Gene Therapy | CI |
| 26/12 | JM Financial Upgrades Aster DM Healthcare to Buy from Add; Price Target is INR760 | MT |
| Capitalization | 29TCr 313.31Cr 266.66Cr 247.65Cr 232.19Cr 432.36Cr 458.4Cr 2.83TCr 1.12TCr 14TCr 1.17TCr 1.15TCr 50TCr | P/E ratio 2026 * |
71.2x | P/E ratio 2027 * | 41.5x |
|---|---|---|---|---|---|
| Enterprise value | 28TCr 304.7Cr 259.33Cr 240.84Cr 225.81Cr 420.48Cr 445.8Cr 2.75TCr 1.09TCr 13TCr 1.14TCr 1.12TCr 48TCr | EV / Sales 2026 * |
4.75x | EV / Sales 2027 * | 2.81x |
| Free-Float |
44.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aster DM Healthcare Limited
| 1 day | -3.65% | ||
| 1 week | -7.37% | ||
| Current month | -9.99% | ||
| 1 month | -7.05% | ||
| 3 months | -22.94% | ||
| 6 months | -7.22% | ||
| Current year | -9.99% |
| 1 week | 539.2 |  | 595.05 |
| 1 month | 539.2 | | 627.8 |
| Current year | 539.2 | | 627.8 |
| 1 year | 387.1 | | 732.2 |
| 3 years | 201.3 | | 732.2 |
| 5 years | 132.55 | | 732.2 |
| 10 years | 78 | | 732.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alisha Moopen
CEO | Chief Executive Officer | 44 | - |
| Director of Finance/CFO | - | 25/05/2023 | |
Sudeep Dey
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 11/04/2020 | |
| Director/Board Member | - | 31/07/2024 | |
| Chairman | 72 | 01/12/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.65% | -7.37% | +11.14% | +152.90% | 325.18Cr | |
| +1.30% | +2.02% | +19.78% | +44.05% | 1.86TCr | |
| -0.18% | -4.20% | -9.11% | -56.95% | 1.49TCr | |
| +0.09% | -5.98% | -1.70% | +56.92% | 1.07TCr | |
| -0.50% | +8.11% | -17.01% | -33.33% | 1.02TCr | |
| -0.15% | -3.79% | +26.26% | +86.56% | 1.01TCr | |
| -0.33% | -1.48% | +3.93% | +58.95% | 999.82Cr | |
| -1.74% | +12.80% | -21.45% | - | 868.17Cr | |
| +0.30% | -5.85% | +32.73% | +197.76% | 693.57Cr | |
| -1.45% | -0.52% | +10.33% | -45.34% | 584.45Cr | |
| Average | -0.64% | -0.72% | +5.49% | +51.28% | 991.66Cr | |
| Weighted average by Cap. | -0.22% | -0.48% | +4.84% | +36.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.87TCr 64Cr 55Cr 51Cr 48Cr 88Cr 94Cr 578.7Cr 229.32Cr 2.77TCr 240.46Cr 235.54Cr 10TCr | 10TCr 110.89Cr 94Cr 88Cr 82Cr 153.02Cr 162.24Cr 1TCr 396.54Cr 4.8TCr 415.82Cr 407.3Cr 18TCr |
| Net income | 406.55Cr 4.44Cr 3.78Cr 3.51Cr 3.29Cr 6.13Cr 6.49Cr 40Cr 16Cr 192.04Cr 17Cr 16Cr 702.76Cr | 1.21TCr 13Cr 11Cr 10Cr 9.8Cr 18Cr 19Cr 119.31Cr 47Cr 571.98Cr 50Cr 49Cr 2.09TCr |
| Net Debt | -788.6Cr -8.61Cr -7.33Cr -6.81Cr -6.38Cr -12Cr -13Cr -78Cr -31Cr -372.51Cr -32Cr -32Cr -1.36TCr | -124.65Cr -1.36Cr -1.16Cr -1.08Cr -1.01Cr -1.88Cr -1.99Cr -12Cr -4.87Cr -59Cr -5.1Cr -5Cr -215.47Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 555.25 ₹ | -3.65% | 3,28,424 |
| 22/26/22 | 576.30 ₹ | +1.36% | 7,44,287 |
| 21/26/21 | 568.55 ₹ | +3.07% | 16,22,641 |
| 20/26/20 | 551.60 ₹ | -3.73% | 17,86,151 |
| 19/26/19 | 573.00 ₹ | -4.40% | 7,52,839 |
Delayed Quote NSE India S.E., January 23, 2026 at 05:19 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ASTERDM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition